Back

Pharmacotherapy in individuals post-aortic valve replacement (TAVI or SAVR) for severe aortic stenosis: a national target trial emulation study of 57,676 individuals

28 August 2026 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Aortic valve stenosis and transcatheter aortic interventions Aortic Valve Stenosis ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Laura Pasea

University College London, London (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Sex differences in clinical characteristics and outcomes of patients with moderate aortic stenosis and regurgitation
Assistant Professor J. Son (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Myocardial blood flow in aortic stenosis: predictors of recovery after aortic valve replacement
Doctor N. Aziminia (London, GB)
Abstract Slides Video
Presentation thumbnail
Heart failure therapy in severe aortic stenosis after surgical or transcatheter aortic valve replacement (The HF-STAR cohort study)
Doctor M. Autherith (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Short-term exposure to high altitude in patients with asymptomatic aortic stenosis
Doctor M. Bigler (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Development of a 1-year mortality risk calculator in severe aortic stenosis incorporating aortic valve replacement within the first year
Doctor A. Roshan (Vancouver, CA)
Abstract Slides

Access the full session

Session thumbnail
Aortic valve stenosis and transcatheter aortic interventions

The Event

Event poster

ESC Congress 2026

28 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Association of SGLT2-inhibitor and GLP1-receptor agonist use with clinical outcomes in aortic stenosis: a large-scale propensity-matched study
28 August 2026
thumbnail
Congress Presentation
Digoxin initiation in advanced heart failure with reduced ejection fraction and atrial fibrillation: a nationwide target trial emulation study
30 August 2026
thumbnail
Congress Presentation
Cardiac resynchronization therapy in heart failure: a target trial emulation study
20 May 2025
thumbnail
Congress Presentation
Cardiovascular outcomes and mortality associated with proton pump inhibitors versus histamine-2 receptor antagonists in patients with heart failure: a target trial emulation study
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources